Our partners have served as Directors of technology transfer offices. Their vast experience provides you with a professional and targeted experience.
I'm Page Heller, President of Hopes Creek. I established Hopes Creek in 2007 to serve the need for short-term assistance in technology management and help with improvement of commercialization services.
I have owned and operated six technology companies in the electronics sector. I have self-funded, angel-funded, venture-funded and formed strategic alliances with major corporations. I know the euphoria and I know the pain of launching a startup. I know what works and what doesn't. You can't get that from a book.
The last sixteen years I have been managing intellectual property for a large organization. I have evaluated more than 600 innovations for commercial potential and I have personally negotiated more than 200 license agreements. I recently negotiated a six million dollar license agreement for one of my clients. I know how to get the deal done.
I'm an investor, also. I know what investors look for. I know what they don't like to hear. I've been there.
Today, I offer assistance to startups by writing business plans and helping with intellectual property strategy. I help well-established companies organize and defend their IP portfolios. I offer assistance to universities and other non-profits by organizing their operations for efficiency, assessing technologies, valuing innovation and more.
I started Hopes Creek with you in mind. Hopes Creek can also provide educational workshops on intellectual property. Train your employees to recognize when they have conceived an invention. Provide the knowledge of how a publication of information can later impact whether or not a patent examiner will accept claims. My team can prepare a workshop for your specific needs.
I hope to be able to serve you today and hope you will join the loyal customers of Hopes Creek. -Page Heller
Jim. Severson specializes in assisting organizations in the commercialization of early-stage technologies. Prior to his current consulting position, Jim was the Vice President Global Networks of Veratect Corporation where he was responsible for the development of collaborative relationships to assist in the verification and assessment of emerging disease outbreaks and events of civil unrest.
Jim was the Vice Provost for Intellectual Property and Technology Transfer at the University of Washington. Jim also was the President of the Cornell Research Foundation where he was responsible for technology transfer from Cornell's Ithaca campus and the Weill Medical College of Cornell University in New York City. Jim also held technology transfer positions at the University of Minnesota, and held positions in new technology assessment and market development at Amersham Corporation.
Jim received both a B.S. and a Ph.D. from Iowa State University, and did postdoctoral research at the University of Southern California. He also held a faculty appointment in the University of Southern California School of Medicine.
Jim is a Past President of the Association of University Technology Managers. In 2005, AUTM awarded Jim its highest honor, the Bayh-Dole award, "in recognition of untiring efforts to foster and promote intellectual property activities on behalf of the university and nonprofit community." Jim has served as member of the Board of Directors of the Council on Governmental Relations (COGR), and he chaired its Contracts and Intellectual Property Committee from 2005 to 2008.
joe fondacaro, emeritus
Joseph Fondacaro received his Ph.D. in Physiology from the University of Cincinnati College of Medicine. Following a 2 year postdoctoral fellowship at Albany Medical Center in New York, he spent 8 years as a faculty member at the Cincinnati College of Medicine and 15 years as a scientist and administrator in the pharmaceutical industry initially with what is now Glaxo SmithKline and later with Marion Merrill Dow (now part of Sanofi-Aventis).
In 1996, Fondacaro joined Cincinnati Children's Hospital Research Foundation to establish the office of technology transfer. He serves on the Board of Trustees for BioStart, a biomedical incubator and the Cincinnati Foundation for Biomedical Research and Education.
He holds a faculty position at the University of Cincinnati College of Medicine and lectures on Ethics in Intellectual Property Management. He serves on several AUTM committees including the Technology Transfer Practice Manual Editorial Committee and the Central Region Planning Committee, lectures in several AUTM courses and has recently served as the AUTM Vice President for Professional Development. Fondacaro is past chair for the Industry-University Transactions Sector of the Licensing Executive Society (LES) and co-founder and chairman of the Cincinnati Chapter of LES. He has published several articles on university licensing and technology transfer and serves on the Editorial Board of Intellectual Property Marketing Advisor. Fondacaro is the founder and Immediate Past Director of the Center for Technology Commercialization and is currently the Executive Director for Strategic Research Alliances for Cincinnati Children's Hospital Medical Center.
Stu Gordon, PhD, retired as Director of the Office of Technology Transfer and Commercialization at California State University at San Bernadino where he served since 2003. In his prior work, he spent 6 years as founding Director of the Technology Transfer Office and Professor of Biology at San Diego State University. Before San Diego, Dr Gordon was Associate Professor of Medicine and Pathology at the University of Colorado Health Sciences Center where he held positions as Director of the Clinical Research Center Laboratory for about 10 years and participated in intellectual property management including Director of the BioMedical Technology Transfer Office for another 10 years.
His primary research focus was the discovery of a unique proteolytic enzyme from cancer cells that activated the blood coagulation cascade, is an effective tumor marker and target for cancer therapy. He has published more than 60 original scientific papers and review articles. Dr. Gordon has made more that 70 invited presentations nationally and internationally. He was a co-editor for an international publication, Blood Coagulation and Fibrinolysis, from1988 to Sept 1998 and was a clinical editorial advisor for Clinical Hemostasis Reviews from 1987 to 1999. He still participates on the review boards for many journals and granting agencies. Dr. Gordon holds 6 patents and has participated in founding 3 companies. He was a founding Board of Directors member for the Colorado BioMedical Venture Center, a biomedical business incubator.
Dr. Gordon received his Bachelor of Science degree in Chemistry from the University of Wisconsin, Madison, his Ph.D. in Medicine from the University of Colorado Health Sciences Center in Denver and did a 2 year postdoctoral fellowship in Biochemistry at Washington University School of Medicine in St. Louis, Missouri.
John Perchorowicz, Ph.D. has over 28 years of experience in triaging, evaluating and developing commercialization strategies for technologies arising from research institutions all over the world, with a particular strength in the pharmaceutical and biomedical disciplines. John's experience includes 22 years of service as Vice President, Business Development for Research Corporation Technologies (RCT) and prior to that, 6 years in the biotechnology industry. In his capacity as RCT's VP, Business Development searching for opportunities appropriate to RCT's business strategy, John has advised many case managers at numerous institutions critically reviewing and creating commercialization strategies. He also assists in managing patent prosecution, negotiating and drafting commercialization arrangements, including licenses, and directing legal proceedings pertaining to the assertion or defense of intellectual property rights deriving from university inventions.
Perchorowicz offers strategic management advice for TTOs. These services are aimed at improving internal decision-making criteria, management processes and performance metrics and include aiding in the identification of those invention disclosures that offer technologies with true commercial promise, and developing comprehensive commercialization plans and patenting strategies, assisting in the direction and management of patent prosecution, implementing technology marketing, negotiating commercialization terms and agreements, and managing the on-going diligence oversight once transfer of the technology has been effected.